Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
No results matched your search
Switzerland Stocks
| Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| Credit Suisse | 11.90 | 12.01 | 11.86 | -0.02 | -0.17% | 8.58M | 22/02 | ||
| Adecco N | 53.24 | 53.62 | 52.92 | +0.24 | +0.45% | 814.62K | 22/02 | ||
| Richemont | 74.36 | 74.74 | 73.88 | +0.66 | +0.90% | 1.16M | 22/02 | ||
| Julius Baer | 40.39 | 40.90 | 39.88 | +0.59 | +1.48% | 868.11K | 22/02 | ||
| ABB | 20.23 | 20.25 | 20.09 | +0.09 | +0.45% | 5.52M | 22/02 | ||
| LafargeHolcim | 48.94 | 49.39 | 48.00 | +0.19 | +0.39% | 1.42M | 22/02 | ||
| Zurich Insurance Group | 326.30 | 326.80 | 325.50 | +0.90 | +0.28% | 356.03K | 22/02 | ||
| Swatch I | 284.10 | 286.40 | 281.20 | +2.90 | +1.03% | 221.17K | 22/02 | ||
| Swiss Life Holding | 418.60 | 420.30 | 414.50 | +3.60 | +0.87% | 170.87K | 22/02 | ||
| Novartis | 90.86 | 90.92 | 89.86 | +0.22 | +0.24% | 3.57M | 22/02 | ||
| Nestle | 90.94 | 91.70 | 90.50 | -0.80 | -0.87% | 6.55M | 22/02 | ||
| Swiss Re | 98.44 | 99.00 | 98.02 | +0.52 | +0.53% | 1.21M | 22/02 | ||
| Roche Holding Participation | 277.20 | 278.20 | 274.50 | +0.15 | +0.05% | 1.50M | 22/02 | ||
| Lonza Group | 286.50 | 288.20 | 284.80 | -0.50 | -0.17% | 233.86K | 22/02 | ||
| Swisscom | 459.50 | 461.30 | 456.90 | +1.80 | +0.39% | 138.21K | 22/02 | ||
| SGS | 2,543.00 | 2,551.00 | 2,505.00 | +43.00 | +1.72% | 24.31K | 22/02 | ||
| Geberit | 403.70 | 407.10 | 401.60 | +2.20 | +0.55% | 108.44K | 22/02 | ||
| Sika | 134.80 | 135.80 | 130.60 | +5.20 | +4.01% | 848.25K | 22/02 | ||
| UBS Group | 12.37 | 12.51 | 12.31 | +0.03 | +0.20% | 15.69M | 22/02 | ||
| Givaudan | 2,470.00 | 2,477.00 | 2,458.00 | +6.00 | +0.24% | 15.13K | 22/02 |
Stock Market News
Roche nearing $5 billion deal to acquire Spark Therapeutics: WSJ
By Reuters - Feb 23, 2019
(Reuters) - Swiss drugmaker Roche Holding (SIX:ROG) AG is nearing a deal to acquire U.S. biotechnology company Spark Therapeutics Inc, the Wall Street Journal reported on...
Third Point claims 300 percent return on activism since 2011
By Reuters - Feb 23, 2019
By Svea Herbst-Bayliss BOSTON (Reuters) - Pushing companies to perform better has earned Third Point a 300 percent return in the last eight years, the hedge fund told investors in...
Don't Be Fooled, This Boring Week in Stocks Was Full of Drama
By Bloomberg - Feb 22, 2019
(Bloomberg) -- It was a heck of a week, considering nothing much happened. U.S. stocks just finished marginally higher for the past four days. The S&P 500 Index rose 0.6...
Stock Markets Analysis & Opinion
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review To Some Candidates
By Zacks Investment Research - Feb 21, 2019
This week Merck (NYSE:MRK) announced a definitive agreement to buy late-stage immunotherapy company Immune Design Corp. (NASDAQ:IMDZ) for approximately $300 million. Its PD-L1 inhibitor Keytruda...
UBS Group AG Slapped With $5.1B Fine For Tax Evasion In France
By Zacks Investment Research - Feb 20, 2019
Recently, Swiss bank, UBS Group AG (NYSE:UBS) and its French unit were found guilty by the French trial court of tax fraud and money laundering against allegations that the bank helped its clients...
Roche's (RHHBY) BLA For Lymphoma Drug Gets Priority Review
By Zacks Investment Research - Feb 19, 2019
Roche (OTC:RHHBY) announced that the FDA has accepted the company’s Biologics License Application (BLA) for anti-CD79b antibody drug conjugate (ADC) polatuzumab vedotin in combination with...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
